| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.AOG.0000240135.13594.07 |
| P698 | PubMed publication ID | 17077226 |
| P50 | author | Richard L. Berkowitz | Q15457278 |
| Ilan E. Timor-Tritsch | Q30505561 | ||
| Lisa M Sullivan | Q37382153 | ||
| George Saade | Q87949010 | ||
| Lorraine Dugoff | Q88999177 | ||
| Sabrina Craigo | Q100746223 | ||
| Mary D'Alton | Q108672326 | ||
| Fergal D. Malone | Q112037230 | ||
| Christine H. Comstock | Q112037520 | ||
| Honor M. Wolfe | Q112045440 | ||
| P2093 | author name string | Keith A Eddleman | |
| David A Luthy | |||
| Kim Dukes | |||
| Stephen R Carr | |||
| Susan Klugman | |||
| T Flint Porter | |||
| Yara Kharbutli | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | miscarriage | Q28693 |
| amniocentesis | Q473768 | ||
| P304 | page(s) | 1067-1072 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Obstetrics and Gynecology | Q7075543 |
| P1476 | title | Pregnancy loss rates after midtrimester amniocentesis. | |
| P478 | volume | 108 |
| Q46033126 | A Priori Attitudes Predict Amniocentesis Uptake in Women of Advanced Maternal Age: A Pilot Study. |
| Q35841761 | A very unusual complication of amniocentesis |
| Q37322417 | Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit analysis based on a large database reflecting the current common practice |
| Q33894437 | Ambivalence toward undergoing invasive prenatal testing: an exploration of its origins |
| Q42196647 | Amniotic fluid and amniotic membrane stem cells: marker discovery. |
| Q48424619 | Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy |
| Q24234586 | Analgesia for amniocentesis or chorionic villus sampling |
| Q24235079 | Analgesia for amniocentesis or chorionic villus sampling |
| Q51308657 | Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening. |
| Q46084560 | Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a single-centre open randomised controlled trial |
| Q33343496 | Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma |
| Q47673360 | Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. |
| Q38049499 | CD117(+) amniotic fluid stem cells: state of the art and future perspectives |
| Q39643958 | Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo |
| Q24651889 | Contemporary diagnosis and management of preterm premature rupture of membranes |
| Q37899884 | Copy-number changes in prenatal diagnosis |
| Q50288230 | Factors that affect the decision to undergo amniocentesis in women with normal Down syndrome screening results: it is all about the age. |
| Q37881971 | Fetal gene therapy: recent advances and current challenges |
| Q82321880 | Fetal loss associated with second trimester amniocentesis |
| Q41276317 | Fetal loss following second trimester amniocentesis. Who is at greater risk? How to counsel pregnant women? |
| Q35034029 | First trimester diagnosis and screening for fetal aneuploidy |
| Q39756897 | Gestation related karyotype, QF-PCR and CGH-array failure rates in diagnostic amniocentesis. |
| Q34121318 | Human amniotic fluid stem cells support undifferentiated propagation and pluripotency of human embryonic stem cell without b-FGF in a density dependent manner |
| Q38198125 | Human amniotic-fluid-derived stem cells: a unique source for regenerative medicine |
| Q38497910 | Identification of novel candidate maternal serum protein markers for Down syndrome by integrated proteomic and bioinformatic analysis |
| Q37568639 | In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. |
| Q61839281 | Influence of anchoring on miscarriage risk perception associated with amniocentesis |
| Q33588817 | Influence of place of residence on indications for genetic amniocentesis in the Pomeranian region of Poland before and after introduction of the Prenatal Screening Program in 2008. |
| Q34554865 | Invasive prenatal genetic testing: A Catholic healthcare provider's perspective |
| Q84135350 | Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes |
| Q81356771 | Management of pregnancy in women with palliated and unpalliated congenital heart defects |
| Q36564375 | Maternal age-based prenatal screening for chromosomal disorders: attitudes of women and health care providers toward changes |
| Q34057503 | Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection |
| Q34043532 | Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. |
| Q36876576 | Mid-trimester amniocentesis fetal loss rate |
| Q44299715 | NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy |
| Q36847554 | Non-invasive Prenatal Testing: Technologies, Clinical Assays and Implementation Strategies for Women's Healthcare Practitioners |
| Q92982636 | Noninvasive Prenatal Testing - When Is It Advantageous to Apply |
| Q34028063 | Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis |
| Q26783426 | Noninvasive prenatal diagnosis |
| Q46550892 | Nuchal translucency thresholds in prenatal screening for Down syndrome and trisomy 18. |
| Q93588821 | Position Statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing |
| Q36784201 | Pre- and post-test genetic counseling for chromosomal and Mendelian disorders |
| Q46419777 | Predictive factors for neonatal survival in women with periviable preterm rupture of the membranes. |
| Q37322448 | Prenatal diagnosis: update on invasive versus noninvasive fetal diagnostic testing from maternal blood |
| Q37787005 | Prenatal genetic screening and diagnosis for pediatricians |
| Q80476622 | Prenatal screening for fetal aneuploidy |
| Q84836506 | Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA |
| Q34272089 | Prevention of maternal cytomegalovirus infection: current status and future prospects |
| Q36034069 | Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel |
| Q35209735 | Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis |
| Q57174843 | Prospective observations study protocol to investigate cost-effectiveness of various prenatal test strategies after the introduction of noninvasive prenatal testing |
| Q37414538 | Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ) |
| Q38219629 | Recent advances in the genetics and management of harlequin ichthyosis |
| Q35034216 | Screening for fetal aneuploidy and neural tube defects |
| Q54382131 | Short-term outcomes after second-trimester genetic amniocentesis in Siriraj Hospital. |
| Q92558269 | Single or double needle insertion in twin's amniocentesis: Does the technique influence the risk of complications? |
| Q34566545 | Spindle shaped human mesenchymal stem/stromal cells from amniotic fluid promote neovascularization |
| Q34961663 | Stem cells derived from amniotic fluid: new potentials in regenerative medicine |
| Q54025333 | The introduction of the absolute risk for the detection of fetal aneuploidies in the first-trimester screening. |
| Q35961717 | The limited effect of information on Israeli pregnant women at advanced maternal age who decide to undergo amniocentesis |
| Q45998316 | The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience. |
| Q38765977 | The yield and complications of amniocentesis performed after 24 weeks of gestation |
| Q34199581 | To VBAC or not to VBAC. |
| Q47779914 | Total pregnancy loss after chorionic villus sampling and amniocentesis: a cohort study |
| Q28385206 | Use of amniotic fluid for determining pregnancies at risk of preterm birth and for studying diseases of potential environmental etiology |
| Q52881355 | [Prenatal diagnostics: current medical aspects]. |
Search more.